Financial stability has eroded significantly, resulting in a negative equity position of -$33.3 million and a precarious current ratio of 0.06 as of 2026Q1.
| Total Current Assets | 850.01K | 3.82M | 2M | 6.91M | 4.74M | 9.42M | 11.03M | 4.09K | 115.71K | 25K |
| Cash & Short-Term Investments | 268.85K | 3.2B | 833.03M | 97.1K | 2.77M | 7.87M | 10.5M | 4.09K | 115.71K | 25K |
| Cash Only | 268.85K | 833.03K | 833.03K | 97.1K | 2.77M | 7.87M | 10.5M | 4.09K | 115.71K | 25K |
| Short-Term Investments | 0 | 0 | 832.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 11.97K | 0 | 1.15M | 5.85M | 527.96K | 589.84K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 578.58 | - | 3.14K | 3.31K | 206.39 | 2.05K | - | - | - | - |
| Inventory | 128.37K | 5.77M | 11.24K | 745.5K | 950.09K | 494.7K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 47.01K | 720.02K | 6.54 | 359.53 | 452.26 | 2.32K | - | - | - | - |
| Other Current Assets | 0 | -3.2B | -885.71M | 0 | 0 | 0 | 384.69K | 0 | 0 | 0 |
| Total Non-Current Assets | 13.06M | 12.7M | 30.14M | 37.67M | 5.99M | 7.25M | 2.06M | 119.44K | 0 | 0 |
| Property, Plant & Equipment | 1.78M | 2.08B | 2.77M | 4.1M | 5.48M | 6.36M | 1.67M | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | 0.00x | 0.05x | 0.16x | 0.17x | 0.02x | - | - | - | - |
| Goodwill | 537.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.94K | 2.78M | 6.11K | 9.44K | 107K | 214K | 321K | 0 | 0 | 0 |
| Long-Term Investments | 57.77M | 10.55M | 27.28M | 22.28M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 61.59K | -2.09B | -310.19K | 11.28M | 405.37K | 668.79K | 72.3K | 119.44K | 0 | 0 |
| Total Assets | 13.91M | 16.52M | 32.14M | 44.58M | 10.74M | 16.66M | 13.1M | 123.53K | 115.71K | 25K |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.01x | 0.09x | 0.01x | - | - | - | - |
| Asset Growth % | -149.32% | -48.62% | -27.89% | 315.25% | -35.58% | 27.24% | 10501.71% | 6.76% | 362.84% | - |
| Total Current Liabilities | 13.34M | 12.22M | 23.41M | 25.89M | 3.64M | 3.61M | 1.23M | 2.98M | 1.65M | 59.9K |
| Accounts Payable | 7.73M | 7.34M | 10.19M | 8.55M | 1.96M | 1.58M | 241.61K | 1.85M | 1.06M | 8.57K |
| Days Payables Outstanding | 279K | 915.37K | 5.93K | 4.13K | 932.28 | 7.37K | 4.96K | - | - | - |
| Short-Term Debt | 3.31M | 2.66B | 5.8M | 16.18M | 409.98K | 700.43K | 587.59K | 165.6K | 163.6K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | -1.96M | -1.58M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.67M | -2.66B | 4.48M | 158.61K | 2.15M | 1.76M | 6.54K | 0 | 0 | 51.33K |
| Current Ratio | 0.06x | 0.31x | 0.09x | 0.27x | 1.30x | 2.61x | 8.99x | 0.00x | 0.07x | 0.42x |
| Quick Ratio | 0.05x | -0.16x | 0.08x | 0.24x | 1.04x | 2.47x | 8.99x | 0.00x | 0.07x | 0.42x |
| Cash Conversion Cycle | -231.41K | - | -2.78K | -455.04 | -273.63 | -3.01K | - | - | - | - |
| Total Non-Current Liabilities | 35.74M | 342.91M | 450.87K | 2.64M | 1.89M | 2.88M | 858.06K | 0 | 1.22M | 25K |
| Long-Term Debt | 0 | 342.9M | 0 | 0 | 0 | 110.04K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 745.15K | 342.9K | 436.35K | 1.04M | 1.89M | 2.77M | 858.06K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 35.45M | 0 | 14.52K | 1.6M | 0 | 0 | 0 | 0 | 0 | 25K |
| Total Liabilities | 49.08M | 12.56M | 23.86M | 28.53M | 5.53M | 6.48M | 2.09M | 2.98M | 1.65M | 84.9K |
| Total Debt | 4.23M | 6.92M | 6.92M | 18.22M | 3.38M | 4.72M | 1.84M | 165.6K | 163.6K | 0 |
| Net Debt | 3.96M | 6.09M | 6.09M | 18.12M | 613.22K | -3.15M | -8.66M | 161.51K | 47.89K | -25K |
| Debt / Equity | -0.12x | 1.75x | 0.84x | 1.14x | 0.65x | 0.46x | 0.17x | - | - | - |
| Debt / EBITDA | -0.23x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.22x | - | - | - | - | - | - | - | - | -0.04x |
| Interest Coverage | -24.47x | -16.92x | -3.76x | -4.07x | -11.10x | -22.92x | -28.51x | -3018.55x | -70.32x | - |
| Total Equity | -35.17M | 3.95M | 8.29M | 16.05M | 5.21M | 10.18M | 11.01M | -2.85M | -1.54M | -59.9K |
| Equity Growth % | -585.45% | -52.29% | -48.36% | 208.22% | -48.86% | -7.54% | 486.07% | -85.6% | -2465.5% | - |
| Book Value per Share | -1743.55 | 105.84 | 628.85 | 12.17 | 1.21 | 0.23 | 0.85 | - | - | - |
| Total Shareholders' Equity | -33.28M | 5.61M | 8.87M | 16.06M | 5.21M | 10.18M | 11.01M | -2.85M | -1.54M | -59.9K |
| Common Stock | 39 | 412 | 130 | 1.32K | 4.31K | 44.53K | 13.08K | 3.92K | 7.53K | 7.1K |
| Retained Earnings | -225.76M | -209.81M | -168.09M | -127.74M | -95.04M | -67.35M | -20.88M | -11.73M | -5.9M | -212.99K |
| Treasury Stock | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K | -189.63K | 0 | 0 |
| Accumulated OCI | 1.36M | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.9M | -1.66M | -583.18K | -9.61K | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent insolvency and dilution
As reported in recent financial statements, Aditxt's total assets have declined from $44.6 million in 2023Q4 to $13.9 million by 2026Q1, signaling a rapid contraction that reflects the company's inability to sustain its asset base while simultaneously accumulating massive losses in its retained earnings account.
The consistent decline in total assets alongside a ballooning deficit in retained earnings suggests that the company is consuming its capital base to fund ongoing operational losses. This trajectory implies that the firm is struggling to maintain the necessary resources to support its research and development initiatives.
Based on the most recent quarterly data, the current ratio has plummeted to a precarious 0.06, indicating that the company's cash reserves of $268.9 thousand are insufficient to cover its immediate short-term obligations, leaving the firm with virtually no buffer against unexpected operational shocks or liquidity events.
A current ratio well below unity suggests that the company is effectively insolvent on a working capital basis. Investors should monitor the firm's reliance on external financing, as the current cash position appears inadequate to support even near-term research milestones without immediate capital infusion.
According to the provided balance sheet data, the company's equity has shifted into a negative position of -$33.3 million as of 2026Q1, which highlights the severe impact of persistent operating losses and the potential for significant shareholder dilution as the firm seeks to recapitalize its operations.
The transition to negative equity suggests that the company's liabilities have outpaced its assets, effectively wiping out the book value for common shareholders. This condition often precedes significant restructuring or dilutive equity offerings, which may further impair the value of existing holdings.
As indicated by the company's historical filings, the presence of goodwill and intangible assets, while currently small at $537.4 thousand, warrants caution, as these figures may not reflect the true impairment risk associated with the company's licensed intellectual property in a distressed clinical development environment.
The reliance on intangible assets to bolster the balance sheet may be misleading if the underlying technology fails to reach clinical validation. Analysts should consider that these assets could be subject to significant write-downs, further pressuring the already negative equity position.
Quick answers to the most common questions about buying ADTX stock.
As of 2025, Aditxt, Inc. (ADTX) had total assets of $16.5M including $3.8M in current assets.
Aditxt, Inc. (ADTX) carries total debt of $6.9M, offset by $3.20B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Aditxt, Inc. (ADTX) has total shareholders' equity (book value) of $5.6M ($105.84 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Aditxt, Inc. (ADTX) reported a current ratio of 0.31x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.